Abstract:
The present invention relates to a method for providing a gene expression profile being predictive for the specific response of an individual tumor to a pharmaceutically effective compound, the use thereof, a microarray wherein the nucleotide sequences attached to the substrate consist of nucleotide sequences corresponding to the predictive genes of said gene expression profile, and a diagnostic kit containing said microarray.
Abstract:
Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined.
Abstract:
Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined.
Abstract:
A system for performing quality control for nucleic acid sample sequencing is disclosed. The system comprises a set of solid supports, each solid support having attached thereto a plurality of nucleic acid sequences, wherein the set comprises plural groups of solid supports and each group contains solid supports having the same nucleic acid sequences attached thereto. The nucleic acid sequences of each group differ from each other. The nucleic acid sequences are synthetically derived, and the nucleic acids sequences are designed such that the nucleic acid sequences produce a predefined pattern of detectable signals during a sequencing run. A method of preparing a quality control for performing nucleic acid sample sequencing, a method of validating a nucleic acid sequencing instrument during a nucleic acid sequencing experiment, and a method of processing nucleic acid sequencing data during a nucleic acid sequencing experiment are also disclosed.
Abstract:
Libraries of nucleic acids encoding chimeric binding polypeptides based on plant scaffold polypeptide sequences. Also described are methods for generating the libraries.
Abstract:
Methods of modulating body fat or weight loss are presented Nucleic acid and protein microarrays that comprise biomolecules associated with an obese host microbiome or a lean host microbiome are utilized for analysis.
Abstract:
The invention is generally directed to antibody variable domains or antibodies, libraries of antibody variable domains or antibodies, methods of making said antibodies and libraries, and methods of treatment comprising administering the generated antibody variable domains or antibodies. Specifically, the invention is directed to novel primer nucleotide sequences that are used to amplify all rearranged sequences of canine variable heavy (VH) and variable light (VL) immunoglobulin chains that have been used in naturally occurring antibody responses. These novel sequences contain canine framework regions and complementarity determining regions which may be used to canine-ize antibodies. Further, these sequences are useful for the identification and targeting of viral and bacterial pathogens, and tumor-associated antigens.
Abstract:
Libraries of nucleic acids encoding chimeric binding polypeptides based on plant scaffold polypeptide sequences. Also described are methods for generating the libraries.
Abstract:
Provided herein are Sirt1 polymorphic variants having a substitution at amino acid residue 107 or nucleotide 373. In certain embodiments, the Sirt1 polypeptide variants have a L107P substitution and the nucleic acid variants have a T373C substitution. Genetic and/or biochemical testing may be performed to identify whether a patient carries one of the disclosed polymorphic variants. Based on the polymorphic variant the patient carries, a medical practitioner may administer an appropriate therapy, such as a sirtuin activator.